<DOC>
	<DOCNO>NCT00565500</DOCNO>
	<brief_summary>Study design : Single center , placebo-controlled , double blind , parallel group . To evaluate potential interaction aspirin ibuprofen celecoxib patient osteoarthritis ( OA ) document stable ischemic heart disease , total 24 patient chronically treat aspirin randomly assign one 3 treatment group : 1 ) celecoxib 200 mg bid ; 2 ) ibuprofen 600 mg tid ; 3 ) placebo .</brief_summary>
	<brief_title>Celecoxib , Ibuprofen Antiplatelet Effect Aspirin</brief_title>
	<detailed_description>Patients arthritis vascular disease may receive NSAIDs lowdose aspirin secondary prevention important vascular event . The use COX-2 inhibitor may potential advantage vs. nonselective NSAIDs reduce probability interfere permanent inactivation COX-1 platelet low-dose aspirin , set . In fact , recent study suggest likelihood COX-inhibitors present pharmacodynamic interaction inversely related COX-2 selectivity . Thus , differently non-selective NSAID ibuprofen , prior administration selective COX-2 inhibitor rofecoxib , antagonize irreversible inhibition induce aspirin healthy subject . Aim study determine whether celecoxib give therapeutic dose steady state alters antiplatelet activity low-dose aspirin , comparison ibuprofen .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>1. male female , age 1875 ; 2. subject osteoarthritis document stable ischemic heart disease ; 3. patient longterm aspirin prophylaxis ischemic condition ; 4. patient require eligible chronic treatment antiinflammatory and/or analgesic drug give control osteoarthritis symptom ; 5. female subject childbearing potential must negative pregnancy test , use adequate contraception study lactating ; 6. write informed consent undergo study procedure . 1. active gastrointestinal disease ( e.g . Crohn 's disease ulcerative colitis ) evidence concomitant disease may lead early termination study ; 2. history active peptic ulceration , gastrointestinal bleeding , esophageal , gastric duodenal ulcer ; 3. know hypersensitivity COX2 inhibitor , analgesic , antipyretic , sulfonamide NSAIDs ; 4. treatment investigational drug within previous 30 day ; 5. previous participation study ; 6. evidence neoplasm severe disease organ , include psychiatric illness ; 7. clinically relevant deviation normal range laboratory test ; 8. recent history suspicion alcohol abuse drug addiction ; 9. subject unlikely collaborative give reliable answer ; 10. pregnancy lactation ; female childbearing potential without clinical accept contraceptive method ; 11. severe pathology interfere treatment clinical instrumental test trial ; 12. intake antiaggregant , anticoagulant , diuretic , betablocker , ACE inhibitor , lithium , methotrexate , cimetidine , digoxin ; 13. contraindication NSAIDs .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>